 ESSA Pharma Inc. ESSA, or the Company Nasdaq: EPIX TSX-V: EPI, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US6.00 per share, before underwriting discounts, for an aggregate offering of approximately US42.6 million the Offering. ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common shares the Option, and the underwriters exercised the Option on July 29, 2020. The proceeds to ESSA from the Offering, including the exercise of the Option, were approximately US45.0 million after deducting underwriting discounts and commissions such commission being equal to 6 of the aggregate gross proceeds of the Offering and other estimated offering expenses. Existing investors participated in the financing along with new investors Pfizer Inc. NYSE: PFE, Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital. 